Is constantly trying to figure out what the h#ll he is doing.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like it is just an iHub glitch. Things look normal trading wise through etrade.
This particular long has been using this quiet time to accumulate some more shares.
Were all still in the 'speculative' zone here at present, but I think that we're still going to see some positive news and positive movement this year.
Definitely a lot less quiet of a trading day today,.... nice 20% rise is always good to see.
Really quiet trading day today.
Interesting upswing today - anybody hear anything newsworthy? I can find anything in my usual places that I look.
Yep,...
I hope you're correct Henkel - but this has been taking a beat-down this last couple of weeks. Even more so than a lot of the rest of the market.
The fact that they have had a bunch of years to finish their anti-herpes, anti-flu, and anti-dengue compounds,... And have not done so,
Suggests that's their working MO.
What an UGLY trading day.
If that wing of the data is double-blinded, then they probably can't see the results until after the study is done and all the data is collected.
Very cool. Thanks for posting and sharing this.
Interesting. It looks like somebody bought over 250K shares near the high of the day and at the end of the day today.
I'll probably just stand where I am through the New Year and then reassess once this stabilizes at some level. I don't tend to trade in and out of stocks, so I was planning on holding what I had for a while anyway.
This piece of my portfolio is just my speculative 'fun' stock/investment money anyway. 90% or more of what I do invest in is boring index fund stuff and stable dividend yielders.
And,... Down we go again today. Ughhh!
Yeah - the market is way overreacting to this capital raise. It appears I should have waited another day or two before pulling that trigger yesterday at $0.79.
This reaction doesn't make much sense.
I think things will rebound nicely in the longer term. Just bought a small block at $0.7911.
I was planning on buying some shares anyway this week. Just got more of them for less money today.
Agreed. I understand the need to sell some stock. Until they have a consistent revenue-generating product, that's always going to be a hazard for AMPE.
IF they are using if (as you state) for something useful that they are ramping up to do, then the longer-term effect will be good. Also - yes - it would be good to hear something on the COVID-related trials in India. No updates in quite some time just adds to the uncertainty and potential volatility.
Sounds promising. It'll depend on follow-through and timing.
Are they going to mold them like little coronavirus particles? Or maybe like little PacMen?
I snagged some this morning at about $3.14. Just a few more to sit on while we are waiting for the Phase III results.
Not that I disagree with this sentiment - but what's their current reasoning and what's their timeline to reach that value?
The $19 MM is good. The recent cash burn is reasonable, but definitely expect that to jump dramatically if/when they ever do get a Phase I trail started for their potential COVID treatment.
Nothing unexpected, but also no actual progress to report.
This statement is too vague to be useful in timeline projection:
I have not been on the Yahoo! chat boards for years, and there is a reason for that.
Yet again - good information,... but pray tell,... when will an actual Phase I trial happen?
Nice summary and it seems like some valid comparisons. Thanks G8TSTFL.
At even $88/share most of us make quite a bit of money. But assuming you're correct about both the projected revenue, and the differences in share numbers - that could work out very much more nicely than $88.
Cheers - for sometime in 2022?
IMO you and TJG are correct. I'll probably add some more shares early next week.
The short-term hit is just a short-term hit here, and the data for the OAK application should be enough to ensure a decent return sometime in 2022.
The data are the data. It's locked and analyzed and reasonably shortly 'we' should hear something about both a BLA and whether the peer-reviewed manuscript are ready.
If that ball was going to be dropped, it would have already been dropped IMO. That - of course - doesn't mean that there will be no more delays or slow movement.
Peer review can be tricky and quirky. Sometimes you'll get reviews and reviewers that are both quick and helpful. Other times you will get reviews and reviewers that disagree or contradict each other. So it's hard to predict how long or convoluted the process to publication will be.
Nice little run-up this afternoon.
Interesting,...
Yeah Dr. S has been out of the picture for a couple of years now. I still occasionally e-mail correspond with him, but he's generally frustrated and as uninformed as the rest of us are at this point.
Any news that anybody has heard about these Phase II trials?
I'm not Frugal,... but I suspect you might be on the mark with your first assumption.
I doubt the second is likely. A buyout, even a 'silent' one (whatever that would entail) would a material event. Discussions about, or maybe even discussions about a framework for a future buyout are a possibility, if a slim one.
I snagged some at about $3.80 at the open,... apparently I should have waited until this afternoon,... Cest la vie? I was planning on holding my shares for a while anyway,...
It suggests to me that some market-connected insider is buying up shares because he/she/they think good things are going to happen here. And that the small fish (like myself for example) are holding what they have, and waiting for that same good set of events.
Correct. The problem has never been the collaborators in academia or industry,... and it may not even have been much of Dr. S's fault as it turns out.
The problem is the current CEO,... And his lack of execution, his lack of follow-through on ANY of the potential drugs to date, and his tendency to flit from one potential target virus to another.
Interesting article. Thanks for sharing this. Quite a bit of this information I have read scattered around in sources, but it's nice to see a concise summary.
If they did wait - it's a bit annoying, but it also makes sense. If the plant is upgraded and the upgraded facility is validated, then they can potentially avoid some FDA hiccups down the line.
We've been patient this long,... a bit longer won't be that bad,... It's better to do something right the first time than to have to do it over because you screwed something up.
I'm not Raffis - but I think this is a big part of the picture with Dr. D.
That would be a nice Thanksgiving, Hanukah, Christmas, Kwanza and New Year's present all rolled into one nice package.
This a the part that kind of pisses me off,... from page 5 of the Annual Report,...